(Sharecast News) - Biopharmaceutical company Amryt Pharma announced on Wednesday that it has received marketing authorisation approval from the Brazilian Health Regulatory Agency (ANVISA) for 'Lojuxta', or lomitapide.
The AIM-traded firm said Lojuxta had been approved as an adjunct to a low-fat diet and other lipid-lowering treatments, with or without low density lipoprotein (LDL) apheresis.
It added that the approval was for its use to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with homozygous familial hypercholesterolaemia (HoFH).
"We are pleased that ANVISA has recognised the significant unmet medical need of patients in Brazil suffering from HoFH and have approved marketing authorisation for Lojuxta to treat adults with this condition," said chief executive officer Dr Joe Wiley.
"Today's news is another milestone in executing our strategy to makeLojuxta®available to HoFH patients in need globally."
At 0944 GMT, shares in Amryt Pharma Holdings were down 3.75% at 192.5p.
11 Jan 2022 14:39
IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York
IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York